Evicenter
P&T meetings

Hovilpri (pritelivir)

Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults

Also known as AIC316
Last updated
239 sources

Section 6 of 6

References

239 sources

  1. Agyemang et al. (2018) (opens in a new tab)
  2. AiCuris AIC316-02-II-01 protocol and statistical plan summary (2017) (opens in a new tab)
  3. AiCuris AIC316-03-I-01 protocol and statistical plan summary (2022) (opens in a new tab)
  4. AiCuris AIC316-03-I-07 protocol (2022) (opens in a new tab)
  5. AiCuris AIC316-03-I-07 statistical analysis plan (2022) (opens in a new tab)
  6. AiCuris corporate presentation (2024) (opens in a new tab)
  7. AiCuris corporate presentation (2025) (opens in a new tab)
  8. AiCuris early access page (opens in a new tab)
  9. AiCuris press release, acquisition by Asahi Kasei (2026) (opens in a new tab)
  10. AiCuris press release, breakthrough therapy designation (2020) (opens in a new tab)
  11. AiCuris press release, early access program with myTomorrows (2020) (opens in a new tab)
  12. AiCuris press release, FDA priority review and ESCMID data (2026) (opens in a new tab)
  13. AiCuris press release, JAMA publication of phase 2 results (2017) (opens in a new tab)
  14. AiCuris press release, phase 2 results at IDWeek (2025) (opens in a new tab)
  15. AiCuris press release, phase 3 start (2021) (opens in a new tab)
  16. AiCuris press release, pipeline milestones (2024) (opens in a new tab)
  17. AiCuris press release, PRIOH-1 enrollment completed (2025) (opens in a new tab)
  18. AiCuris press release, PRIOH-1 HIV subgroup at CROI (2026) (opens in a new tab)
  19. AiCuris press release, PRIOH-1 phase 2 initiation (2017) (opens in a new tab)
  20. AiCuris press release, PRIOH-1 phase 3 data at Tandem (2026) (opens in a new tab)
  21. AiCuris press release, PRIOH-1 topline results (2025) (opens in a new tab)
  22. AiCuris press release, strategic shift (2023) (opens in a new tab)
  23. Albrecht et al. (2021) (opens in a new tab)
  24. Allen et al. (2025) (opens in a new tab)
  25. ANSM pritelivir compassionate access record (2023) (opens in a new tab)
  26. Anton-Vazquez et al. (2020) (opens in a new tab)
  27. Ariza-Heredia et al. (2018) (opens in a new tab)
  28. Asahi Kasei briefing material, Aicuris acquisition (2026) (opens in a new tab)
  29. Asahi Kasei briefing question and answer summary, Aicuris acquisition (2026) (opens in a new tab)
  30. Asahi Kasei press release, Aicuris acquisition agreement (2026) (opens in a new tab)
  31. Asahi Kasei press release, Aicuris acquisition completed (2026) (opens in a new tab)
  32. Asahi Kasei Therapeutics Hovilpri healthcare professional website (2026) (opens in a new tab)
  33. Asahi Kasei Therapeutics press release, Hovilpri FDA approval (2026) (opens in a new tab)
  34. Asahi Kasei Therapeutics press release, pharmaceutical brand integration (2026) (opens in a new tab)
  35. Assembly Biosciences press release (2026) (opens in a new tab)
  36. Avery et al. (2016) (opens in a new tab)
  37. Bacon et al. (2003) (opens in a new tab)
  38. Baranovskiy et al. (2025) (opens in a new tab)
  39. Bausch Aldara prescribing information (2024) (opens in a new tab)
  40. Berger et al. (2026) (opens in a new tab)
  41. Betz et al. (2002) (opens in a new tab)
  42. Birch et al. (1992) (opens in a new tab)
  43. Birkmann (2025b) (opens in a new tab)
  44. Birkmann and Saunders (2025a) (opens in a new tab)
  45. Birkmann et al. (2022) (opens in a new tab)
  46. Birkmann et al. (2025c) (opens in a new tab)
  47. Biswas et al. (2007) (opens in a new tab)
  48. Biswas et al. (2008) (opens in a new tab)
  49. Biswas et al. (2014) (opens in a new tab)
  50. Boivin et al. (1993) (opens in a new tab)
  51. Bonsmann et al. (2024) (opens in a new tab)
  52. Bosetti et al. (2023) (opens in a new tab)
  53. Brummitt (2006) (opens in a new tab)
  54. Bryant et al. (2025) (opens in a new tab)
  55. Burrel et al. (2010) (opens in a new tab)
  56. Burrel et al. (2013) (opens in a new tab)
  57. Burrel et al. (2014) (opens in a new tab)
  58. Bussini et al. (2025) (opens in a new tab)
  59. Cannon et al. (2021) (opens in a new tab)
  60. CDC HIV Fast Facts (2024) (opens in a new tab)
  61. Chakrabarti et al. (2000) (opens in a new tab)
  62. Chatis et al. (1989) (opens in a new tab)
  63. Chemaly et al. (2025) (opens in a new tab)
  64. Chemaly et al. (2026a) (opens in a new tab)
  65. Chemaly et al. (2026b) (opens in a new tab)
  66. Chemaly et al. (2026c) (opens in a new tab)
  67. Chen et al. (2000) (opens in a new tab)
  68. Christophers et al. (1998) (opens in a new tab)
  69. CIBMTR Summary Slides (2025) (opens in a new tab)
  70. ClinicalTrials.gov NCT01047540 (opens in a new tab)
  71. ClinicalTrials.gov NCT01047540 (opens in a new tab)
  72. ClinicalTrials.gov NCT01658826 (opens in a new tab)
  73. ClinicalTrials.gov NCT01658826 (opens in a new tab)
  74. ClinicalTrials.gov NCT01658826 (opens in a new tab)
  75. ClinicalTrials.gov NCT02871492 (opens in a new tab)
  76. ClinicalTrials.gov NCT02871492 (opens in a new tab)
  77. ClinicalTrials.gov NCT02871492 (opens in a new tab)
  78. ClinicalTrials.gov NCT03073967 (opens in a new tab)
  79. ClinicalTrials.gov NCT04165122 (opens in a new tab)
  80. ClinicalTrials.gov NCT04539483 (opens in a new tab)
  81. ClinicalTrials.gov NCT04979975 (opens in a new tab)
  82. ClinicalTrials.gov NCT05513625 (opens in a new tab)
  83. ClinicalTrials.gov NCT05513625 (opens in a new tab)
  84. ClinicalTrials.gov NCT05671029 (opens in a new tab)
  85. ClinicalTrials.gov NCT05671029 (opens in a new tab)
  86. ClinicalTrials.gov NCT05671029 (opens in a new tab)
  87. ClinicalTrials.gov NCT05844436 (opens in a new tab)
  88. ClinicalTrials.gov NCT06385327 (opens in a new tab)
  89. ClinicalTrials.gov NCT06435507 (opens in a new tab)
  90. ClinicalTrials.gov NCT06698575 (opens in a new tab)
  91. ClinicalTrials.gov NCT07387367 (opens in a new tab)
  92. Clinigen Foscavir prescribing information (2020) (opens in a new tab)
  93. CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
  94. CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026) (opens in a new tab)
  95. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  96. Collot et al. (2016) (opens in a new tab)
  97. Dähne et al. (2025) (opens in a new tab)
  98. Danve-Szatanek et al. (2004) (opens in a new tab)
  99. de Vries et al. (2024) (opens in a new tab)
  100. Devine et al. (2022) (opens in a new tab)
  101. Domingo et al. (2021) (opens in a new tab)
  102. ECIL-2 HSV recommendations (2007) (opens in a new tab)
  103. Edlefsen et al. (2016) (opens in a new tab)
  104. EMA paediatric investigation plan decision (2021) (opens in a new tab)
  105. EMA paediatric investigation plan record (2021) (opens in a new tab)
  106. Emergent Tembexa prescribing information (2021) (opens in a new tab)
  107. Engel et al. (1990) (opens in a new tab)
  108. Englund et al. (1990) (opens in a new tab)
  109. Epstein et al. (2016) (opens in a new tab)
  110. Erard et al. (2007) (opens in a new tab)
  111. Erb-Zohar et al. (2024) (opens in a new tab)
  112. Erlich et al. (1989a) (opens in a new tab)
  113. Erlich et al. (1989b) (opens in a new tab)
  114. EU Clinical Trials Information System 2023-510088-37-00 (opens in a new tab)
  115. EU Clinical Trials Register 2020-004940-27 (opens in a new tab)
  116. FAMHP pritelivir compassionate use programme summary (2022) (opens in a new tab)
  117. FDA Hovilpri approval announcement (2026) (opens in a new tab)
  118. FDA Novel Drug Approvals for 2026 (2026) (opens in a new tab)
  119. Field et al. (2013) (opens in a new tab)
  120. Fischer et al. (2026) (opens in a new tab)
  121. Fred Hutch (2016) (opens in a new tab)
  122. Frobert et al. (2014) (opens in a new tab)
  123. Gaudreau et al. (1998) (opens in a new tab)
  124. Gege and Kleymann (2026) (opens in a new tab)
  125. Ghislanzoni et al. (2006) (opens in a new tab)
  126. GlaxoSmithKline Valtrex prescribing information (2025) (opens in a new tab)
  127. GlaxoSmithKline Zovirax injection prescribing information (2019) (opens in a new tab)
  128. Hammond et al. (2024) (opens in a new tab)
  129. Hardy (1992) (opens in a new tab)
  130. Harpaz et al. (2016) (opens in a new tab)
  131. Heidenreich et al. (2020) (opens in a new tab)
  132. Henze et al. (2022) (opens in a new tab)
  133. Hijano et al. (2026) (opens in a new tab)
  134. Hirokawa et al. (2011) (opens in a new tab)
  135. Hovilpri prescribing information (2026) (opens in a new tab)
  136. Huntjens et al. (2023) (opens in a new tab)
  137. Ibrahim et al. (2026) (opens in a new tab)
  138. Innovative Molecules press release (2026) (opens in a new tab)
  139. Javaly et al. (1999) (opens in a new tab)
  140. Kakiuchi et al. (2017) (opens in a new tab)
  141. Kaufman et al. (2008) (opens in a new tab)
  142. Kawamura et al. (2024) (opens in a new tab)
  143. Kawashima et al. (2022) (opens in a new tab)
  144. Kawashima et al. (2023) (opens in a new tab)
  145. KEGG DRUG D12811 (opens in a new tab)
  146. Kessler et al. (1996) (opens in a new tab)
  147. Kim et al. (2011) (opens in a new tab)
  148. Kleymann et al. (2002) (opens in a new tab)
  149. Koinuma et al. (2025) (opens in a new tab)
  150. Kong et al. (2025) (opens in a new tab)
  151. Kotton and Kotton (2022) (opens in a new tab)
  152. Kotton et al. (2025) (opens in a new tab)
  153. Kotton et al. (2026a) (opens in a new tab)
  154. Kotton et al. (2026b) (opens in a new tab)
  155. Kropeit et al. (2023) (opens in a new tab)
  156. Labcorp (opens in a new tab)
  157. Labiotech (2017) (opens in a new tab)
  158. Lalezari et al. (1997) (opens in a new tab)
  159. Langston et al. (2002) (opens in a new tab)
  160. Lascaux et al. (2012) (opens in a new tab)
  161. Lee and Zuckerman (2019) (opens in a new tab)
  162. Lee et al. (2018) (opens in a new tab)
  163. Leeyaphan et al. (2022) (opens in a new tab)
  164. Levin et al. (2004) (opens in a new tab)
  165. Lueck et al. (2025) (opens in a new tab)
  166. Lueck et al. (2026) (opens in a new tab)
  167. Martinez et al. (2006) (opens in a new tab)
  168. Martinson and Lapham (2024) (opens in a new tab)
  169. McElhiney (2006) (opens in a new tab)
  170. McQuillan et al. (2018) (opens in a new tab)
  171. Molina et al. (2026a) (opens in a new tab)
  172. Molina et al. (2026b) (opens in a new tab)
  173. Muluneh et al. (2013) (opens in a new tab)
  174. Murphy et al. (1992) (opens in a new tab)
  175. Mylan cidofovir injection prescribing information (2021) (opens in a new tab)
  176. myTomorrows pritelivir early access page (opens in a new tab)
  177. Nanovskaya et al. (2026) (opens in a new tab)
  178. NCCN Prevention and Treatment of Cancer-Related Infections Guidelines (2026) (opens in a new tab)
  179. NCI Drug Dictionary (opens in a new tab)
  180. NIH HIV Opportunistic Infections Guidelines (2025) (opens in a new tab)
  181. Novartis Famvir prescribing information (2018) (opens in a new tab)
  182. Nunn et al. (2026) (opens in a new tab)
  183. Papanicolaou et al. (2026a) (opens in a new tab)
  184. Papanicolaou et al. (2026b) (opens in a new tab)
  185. Papanicolaou et al. (2026c) (opens in a new tab)
  186. Patel et al. (2025a) (opens in a new tab)
  187. Patel et al. (2025b) (opens in a new tab)
  188. Patil et al. (2026) (opens in a new tab)
  189. Payne et al. (2026) (opens in a new tab)
  190. Perkins et al. (2011) (opens in a new tab)
  191. Pharmobedient Zovirax oral prescribing information (2025) (opens in a new tab)
  192. Piperi et al. (2024) (opens in a new tab)
  193. Piret and Boivin (2011) (opens in a new tab)
  194. Piret and Boivin (2016) (opens in a new tab)
  195. PMDA Amenalief review report (2017) (opens in a new tab)
  196. Purssell et al. (2024) (opens in a new tab)
  197. Quenelle et al. (2018) (opens in a new tab)
  198. Renzoni et al. (2025) (opens in a new tab)
  199. Reyes et al. (2003) (opens in a new tab)
  200. Ruebsamen-Schaeff and Buschmann (2019) (opens in a new tab)
  201. Safrin et al. (1990) (opens in a new tab)
  202. Safrin et al. (1991) (opens in a new tab)
  203. Safrin et al. (1994) (opens in a new tab)
  204. Sallée and Boutolleau (2024b) (opens in a new tab)
  205. Sallée et al. (2024a) (opens in a new tab)
  206. Sandoz trifluridine ophthalmic solution prescribing information (2024) (opens in a new tab)
  207. Sasso et al. (2020) (opens in a new tab)
  208. Sato et al. (2026) (opens in a new tab)
  209. Sauerbrei et al. (2016) (opens in a new tab)
  210. Saunders et al. (2016) (opens in a new tab)
  211. Sbidian et al. (2013) (opens in a new tab)
  212. Schalkwijk et al. (2022) (opens in a new tab)
  213. Schalkwijk et al. (2024) (opens in a new tab)
  214. Schiffer et al. (2016) (opens in a new tab)
  215. Schmidt et al. (2015) (opens in a new tab)
  216. Schultz et al. (2024) (opens in a new tab)
  217. Seang et al. (2014) (opens in a new tab)
  218. Serris et al. (2022) (opens in a new tab)
  219. Shafat et al. (2025) (opens in a new tab)
  220. Shehadeh et al. (2026) (opens in a new tab)
  221. Sims et al. (2007) (opens in a new tab)
  222. Snoeck et al. (1994) (opens in a new tab)
  223. Srinivasan and Ho (2023) (opens in a new tab)
  224. Stránská et al. (2005) (opens in a new tab)
  225. Styczynski et al. (2009) (opens in a new tab)
  226. Tappero et al. (1995) (opens in a new tab)
  227. Tayyar and Ho (2023) (opens in a new tab)
  228. Tomblyn et al. (2009) (opens in a new tab)
  229. University of Washington Laboratory Medicine (opens in a new tab)
  230. University of Washington Laboratory Medicine HSVDR test guide (opens in a new tab)
  231. Voigt et al. (2016) (opens in a new tab)
  232. Wald et al. (2014) (opens in a new tab)
  233. Wald et al. (2016) (opens in a new tab)
  234. Wald et al. (2026) (opens in a new tab)
  235. Wauters et al. (2012) (opens in a new tab)
  236. Whitley and Prichard (2014) (opens in a new tab)
  237. Workowski et al. (2021) (opens in a new tab)
  238. Yao et al. (2025) (opens in a new tab)
  239. Yu et al. (2026) (opens in a new tab)